Does statins promote vascular calcification in chronic kidney disease?

Area of Science:

• Nephrology
• Cardiology
• Biochemistry

Background:

• Cardiovascular disease (CVD) and coronary artery calcification (CAC) are significant concerns in end-stage renal disease (ESRD).
• Statins have not demonstrated improved survival in ESRD patients, and their impact on vascular calcification remains unclear.
• Inflammatory biomarkers also play a role in CVD within the ESRD population.

Purpose of the Study:

• To investigate the associations between CAC, inflammatory biomarkers, statin use, and all-cause mortality in patients with ESRD.
• To explore the effect of statins on CAC progression and vitamin K metabolism in vitro.

Main Methods:

• Analysis of CAC score, interleukin-6 (IL-6), high-sensitivity C-reactive protein (hsCRP), tumour necrosis factor (TNF), statin use, and mortality in 240 ESRD patients.
• Repeated cardiac CT scans in 35 patients after 1.5 years to assess CAC progression.
• In vitro studies using human vascular smooth muscle cells (hVSMCs) to examine vitamin K metabolism.

Main Results:

• An elevated CAC score (>100 Agatston Units) was present in 53% of patients.
• Independent predictors of higher CAC score included age, male gender, diabetes, and statin use.
• Statin therapy was associated with greater CAC progression, and in vitro, statins impaired menaquinone-4 synthesis in hVSMCs.

Conclusions:

• Elevated CAC is a mortality risk factor in ESRD, independent of inflammation.
• Further research is needed to determine if statins exacerbate vascular calcification and inhibit vitamin K synthesis in ESRD patients.